These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27069131)

  • 21. Eribulin shows high concentration and long retention in xenograft tumor tissues.
    Sugawara M; Condon K; Liang E; DesJardins C; Schuck E; Kusano K; Lai WG
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):377-384. PubMed ID: 28664226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical benefit of eribulin (Halaven
    Koyama N; Taniguchi S; Kodama K; Tohyama O; Hasegawa H; Semba T
    Nihon Yakurigaku Zasshi; 2016; 148(6):329-333. PubMed ID: 27904013
    [No Abstract]   [Full Text] [Related]  

  • 23. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
    Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eribulin in Cancer Treatment.
    Swami U; Shah U; Goel S
    Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
    Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
    Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
    Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
    Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Class III
    Yahiro K; Matsumoto Y; Fukushi JI; Kawaguchi KI; Endo M; Setsu N; IIda K; Fukushima S; Nakagawa M; Kimura A; Oda Y; Nakashima Y
    Anal Cell Pathol (Amst); 2018; 2018():8987568. PubMed ID: 30034996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma.
    Nakano T; Fujimoto K; Tomiyama A; Takahashi M; Achiha T; Arita H; Kawauchi D; Yasukawa M; Masutomi K; Kondo A; Narita Y; Maehara T; Ichimura K
    Cancer Sci; 2022 Feb; 113(2):697-708. PubMed ID: 34839570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Tanaka S; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):401-410. PubMed ID: 29277801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
    Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
    Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions.
    Towle MJ; Salvato KA; Wels BF; Aalfs KK; Zheng W; Seletsky BM; Zhu X; Lewis BM; Kishi Y; Yu MJ; Littlefield BA
    Cancer Res; 2011 Jan; 71(2):496-505. PubMed ID: 21127197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.
    Hayasaka N; Takada K; Nakamura H; Arihara Y; Kawano Y; Osuga T; Murase K; Kikuchi S; Iyama S; Emori M; Sugita S; Hasegawa T; Takasawa A; Miyanishi K; Kobune M; Kato J
    Sci Rep; 2019 Apr; 9(1):5759. PubMed ID: 30962488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
    Mani S; Swami U
    Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
    Tanaka S; Ishii T; Sato F; Toi M; Itou J
    Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.
    Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K
    Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin.
    Hinz TK; Kalkur R; Rabinovitch J; Hinkle W; Heasley LE
    Mol Pharmacol; 2021 Aug; 100(2):144-154. PubMed ID: 34031188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma.
    De Vita A; Miserocchi G; Recine F; Mercatali L; Pieri F; Medri L; Bongiovanni A; Cavaliere D; Liverani C; Spadazzi C; Amadori D; Ibrahim T
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27918490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.